Abstract 1478P
Background
There is limited research evaluating trends in the use of regimen sequences among patients (pts) with metastatic pancreatic cancer (m-PANC).
Methods
We identified pts with m-PANC using ICD-10 diagnosis codes in the 2016-2019 Medicare Parts A/B/D 100% Research Identifiable Files. Study pts had 2+ claims with a pancreatic cancer diagnosis and Medicare FFS coverage for 6 months pre- and 3 months post-metastasis diagnosis. A line of therapy (LOT) was assigned based on the order and number of therapies used in each sequence (first, second, or third-line). Regimen sequences had no subsequent chemotherapy following the last regimen within a sequence. We examined one-line, two-line, and three-line sequences.
Results
We identified 31,782 total pts with 21,304 one-line sequences, 7,352 two-line sequences, and 3,126 three-line sequences between 2016 and 2019. Of these, 69% received chemotherapy in 2019, compared to 56% in 2016. In 2019, fewer pts used one-line sequences (41%) and more pts used two- or three-line sequences (28%), compared to 47% and 9%, respectively, in 2016. Among pts receiving two-line sequences, sequences consisting of FOLFIRINOX (FFX) to gemcitabine/nab-paclitaxel (gem/nab) or gem/nab to liposomal irinotecan had the largest increase (from 10% and 5%, respectively, in 2016 to 14% and 11% in 2019). Among pts receiving three-line sequences, the sequences with the largest increase in utilization were FFX to gem/nab to liposomal irinotecan or gem/nab to liposomal irinotecan to FOLFOX (1% and 0% respectively, of all pts with three-line sequences in 2016, compared to 4% and 5% in 2019).
Conclusions
The use of two- and three- line sequences increased consistently from 2016 to 2019. Sequences containing liposomal irinotecan in second and third line are the primary drivers of this increase.
Clinical trial identification
Editorial acknowledgement
Legal entity responsible for the study
The authors.
Funding
Ipsen Biopharmaceuticals Inc.
Disclosure
G. Dieguez: Financial Interests, Institutional, Sponsor/Funding: Ipsen Biopharmaceuticals Inc. S. Tomicki: Financial Interests, Institutional, Sponsor/Funding: Ipsen Biopharmaceuticals Inc. D. DeStephano: Financial Interests, Institutional, Sponsor/Funding: Ipsen Biopharmaceuticals Inc. P. Cockrum: Financial Interests, Institutional, Leadership Role: Ipsen Biopharmaceuticals Inc. G. Kim: Financial Interests, Institutional, Sponsor/Funding: Ipsen Biopharmaceuticals Inc.